K111723 is an FDA 510(k) clearance for the TURBOHAWK PERIPHERAL PLAQUE EXCISION SYSTEM. Classified as Catheter, Peripheral, Atherectomy (product code MCW), Class II - Special Controls.
Submitted by Ev3, Inc. (Plymouth, US). The FDA issued a Cleared decision on October 27, 2011 after a review of 129 days - within the typical 510(k) review window.
This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.4875 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.
View all Ev3, Inc. devices
NCT00733135
Completed
Interventional
Industry-sponsored
Study of the SilverHawk™ /TurboHawk™ Plaque Excision Systems Used With SpiderFX to Treat Calcified Peripheral Arterial Disease (DEFINITIVE Ca++)
Determination of Safety and Effectiveness of the SilverHawk™ Peripheral Plaque Excision System for Calcium (SilverHawk LS-C) and the SpiderFX™ Embolic Protection Device for the Treatment of Calcified Peripheral Arterial Disease in the Superficial Femoral and/or the Popliteal Arteries (DEFINITIVE Ca++)
| Condition studied |
Peripheral Arterial Disease |
| Study design |
Single group |
| Eligibility |
All sexes
· 18 Years+
|
| Principal investigator |
Daniel Clair, MD |
| Sponsor |
Medtronic Endovascular
(industry)
|
Started 2008-10-01
→
Primary completion 2010-11-01
Primary outcome
Successful Revascularization
Secondary outcome
Technical Procedural Success
View full study on ClinicalTrials.gov